Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes

References

• American Diabetes Association Diabetes Statistics Data from the 2011 National Diabetes Fact Sheet Available from: http://www.diabetes.org/diabetes-basics/diabetes-statistics/ Accessed May 30, 2012
   Google Scholar
• Singh S Loke YK Furberg CD Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 2007 298 10 1189 1195 17848653
   PubMed Web of Science ®Google Scholar
• Hummel CS Lu C Loo DD Hirayama BA Voss AA Wright EM Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2 Am J Physiol Cell Physiol 2011 300 1 C14 C21 20980548
   PubMed Web of Science ®Google Scholar
• Sabino-Silva R Mori RC David-Silva A Okamoto MM Freitas HS Machado UF The Na (+)/glucose cotransporters: from genes to therapy Braz J Med Biol Res 2010 43 11 1019 1026 21049241
   PubMed Web of Science ®Google Scholar
• Wright EM Renal Na (+)-glucose cotransporters Am J Physiol Renal Physiol 2001 280 1 F10 F18 11133510
   PubMed Web of Science ®Google Scholar
• Santer R Calado J Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target Clin J Am Soc Nephrol 2010 5 1 133 141 19965550
   PubMed Web of Science ®Google Scholar
• Santer R Kinner M Lassen CL Molecular analysis of the SGLT2 gene in patients with renal glucosuria J Am Soc Nephrol 2003 14 11 2873 2882 14569097
   PubMed Web of Science ®Google Scholar
• Wright EM Hirayama BA Loo DF Active sugar transport in health and disease J Intern Med 2007 261 1 32 43 17222166
   PubMed Web of Science ®Google Scholar
• Tabatabai NM Sharma M Blumenthal SS Petering DH Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats Diabetes Res Clin Pract 2009 83 1 e27 e30 19095325
   PubMedGoogle Scholar
• Rahmoune H Thompson PW Ward JM Smith CD Hong G Brown J Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 2005 54 12 3427 3434 16306358
   PubMed Web of Science ®Google Scholar
• Ehrenkranz JR Lewis NG Kahn CR Roth J Phlorizin: a review Diabetes Metab Res Rev 2005 21 1 31 38 15624123
   PubMed Web of Science ®Google Scholar
• Najafian M Jahromi MZ Nowroznejhad MJ Phloridzin reduces blood glucose levels and improves lipids metabolism in streptozotocin-induced diabetic rats Mol Biol Rep 2012 39 5 5299 5306 22167331
   PubMed Web of Science ®Google Scholar
• Katsuno K Fujimori Y Takemura Y Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level J Pharmacol Exp Ther 2007 320 1 323 330 17050778
   PubMed Web of Science ®Google Scholar
• Dobbins RL O’Connor-Semmes R Kapur A Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients Diabetes Obes Metab 2012 14 1 15 22 21733056
   PubMed Web of Science ®Google Scholar
• Komoroski B Vachharajani N Boulton D Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 2009 85 5 520 526 19129748
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Chang M Hasegawa M Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium- glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus Diabetes Obes Metab 2011 13 4 357 365 21226818
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Liu X Zhang W Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects Diabetes Obes Metab 2011 13 8 770 773 21435141
   PubMed Web of Science ®Google Scholar
• Komoroski B Vachharajani N Feng Y Li L Kornhauser D Pfister M Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 2009 85 5 513 519 19129749
   PubMed Web of Science ®Google Scholar
• List JF Woo V Morales E Tang W Fiedorek FT Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 2009 32 4 650 657 19114612
   PubMed Web of Science ®Google Scholar
• Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, Phase 3 trial Diabetes Care 2010 33 10 2217 2224 20566676
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Pieters A Bastien A List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 2010 375 9733 2223 2233 20609968
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren O Kullberg J Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 2012 97 3 20 31 http://jcem.endojournals.org/
   Web of Science ®Google Scholar
• Nauck MA Del Prato S Meier JJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 9 2015 2022 21816980
   PubMed Web of Science ®Google Scholar
• Strojek K Yoon KH Hruba V Elze M Langkilde AM Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 2011 13 10 928 938 21672123
   PubMed Web of Science ®Google Scholar
• Wilding JP Norwood P T’joen C Bastien A List JF Fiedorek FT A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 2009 32 9 1656 1662 19528367
   PubMed Web of Science ®Google Scholar
• Zhang L Feng Y List J Kasichayanula S Pfister M Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight Diabetes Obes Metab 2010 12 6 510 516 20518806
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Soler NG Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 2012 156 6 405 415 22431673
   PubMed Web of Science ®Google Scholar
• Henry RR Murray AV Marmolejo MH Hennicken D Ptaszynska A List JF Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Int J Clin Pract 2012 66 5 446 456 22413962
   PubMed Web of Science ®Google Scholar
• Carlson GF Tou CK Parikh S Birmingham BK Butler K Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study Diabetes Ther 2011 2 3 123 132 22127822
   PubMedGoogle Scholar
• Kasichayanula S Liu X Zhang W Pfister M LaCreta FP Boulton DW Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study Clin Ther 2011 33 11 1798 1808 22030444
   PubMed Web of Science ®Google Scholar
• European Medicine’s Agency Summary of opinion: Forziga Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002322/WC500125684.pdf Accessed May 30, 2012
   Google Scholar
• Kasichayanula S Chang M Liu X Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin Adv Ther 2012 29 2 163 177 22271159
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Liu X Shyu WC Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects Diabetes Obes Metab 2011 13 1 47 54 21114603
   PubMed Web of Science ®Google Scholar
• Jones D Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor Nat Rev Drug Discov 2011 10 9 645 646 21878967
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration FDA briefing document: NDA 202293 dapagliflozin tablets, 5 and 10 mg sponsor: Bristol-Myers Squibb Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf Accessed May 30, 2012
   Google Scholar
• Sha S Devineni D Ghosh A Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Diabetes Obes Metab 2011 13 7 669 672 21457428
   PubMed Web of Science ®Google Scholar
• Devineni D Morrow L Hompesch M Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin Diabetes Obes Metab 2012 14 6 539 545 22226086
   PubMed Web of Science ®Google Scholar
• Rosenstock J Aggarwal N Polidori D Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 2012 35 6 1232 1238 22492586
   PubMed Web of Science ®Google Scholar
• Veltkamp SA Kadokura T Krauwinkel WJ Smulders RA Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects Clin Drug Investig 2011 31 12 839 851
   PubMed Web of Science ®Google Scholar
• Schwartz SL Akinlade B Klasen S Kowalski D Zhang W Wilpshaar W Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus Diabetes Technol Ther 2011 13 12 1219 1227 21854192
   PubMed Web of Science ®Google Scholar
• Grempler R Thomas L Eckhardt M Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 2012 14 1 83 90 21985634
   PubMed Web of Science ®Google Scholar
• Thomas L Grempler R Eckhardt M Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats Diabetes Obes Metab 2012 14 1 94 96 21985693
   PubMed Web of Science ®Google Scholar
• Suzuki M Honda K Fukazawa M Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice J Pharmacol Exp Ther 2012 341 3 692 701 22410641
   PubMed Web of Science ®Google Scholar
• Nair S Wilding JP Sodium glucose co transporter 2 inhibitors as a new treatment for diabetes mellitus J Clin Endocrinol Metab 2010 95 1 34 42 http://jcem.endojournals.org/ 19892839
   PubMed Web of Science ®Google Scholar